Eli Lilly Announces 3 Infectious Disease Acquisitions in One Day

Eli Lilly (NYSE: LLY) today announced three separate acquisitions in the infectious disease space, signaling a potential strategic shift toward diversifying revenue streams following the massive success of its obesity drugs Mounjaro and Zepbound.

Deal Details

The aggregate value of the three acquisitions has not been disclosed, but is expected to range from hundreds of millions to billions of dollars. The target companies are developing treatments for infectious diseases such as tuberculosis, malaria, and hospital-acquired infections.

Rationale for the Deals

Lilly aims to reduce its dependence on obesity and diabetes drugs, which currently account for the majority of its revenue. The infectious disease market is large and growing, especially with rising antimicrobial resistance.

Regulatory Challenges

The deals are expected to undergo antitrust review in the US and Europe, but given the relatively small size of the targets, approvals are likely without major hurdles.

Impact on Stock

LLY shares did not move significantly after the announcement, as investors await more details on deal values and execution plans. Analysts view the move as positive long-term but not immediately accretive to earnings.